The groups spend big on Terns and Arcellx.
ApexOnco Front Page
Recent articles
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
The Chinese company will start the first of four pivotal trials of its PD-L1 ADC in April.
First human data on MK-2010 are imminent.
The company’s TRPV1 antagonist looks doomed.
The company reveals its anti-GPRC5D T-cell engager.
But this comes in second-line breast cancer, a use the group isn’t pursuing.
The company admits defeat with zelenectide.
